Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lifecare AS ( (DE:LFC0) ) has shared an announcement.
Lifecare ASA has published its Q3 2025 financial report, highlighting significant progress in its development of a miniaturized, implantable Continuous Glucose Monitoring system. The company secured NOK 80 million to support its development and regulatory milestones, finalized product design for the veterinary market, and is in the final phase of regulatory review for human clinical trials. Despite liquidity constraints causing temporary production slowdowns, Lifecare is preparing for a rights issue to raise additional funds. Early results from trials in dogs show promising biocompatibility and data transmission, with human trials expected to start in early 2026, paving the way for a commercial launch in Europe by 2027.
More about Lifecare AS
Lifecare ASA is a medical sensor company focused on developing next-generation Continuous Glucose Monitoring (CGM) systems. The company utilizes osmotic pressure as a sensing principle, aiming to monitor various body analytes and molecules in both humans and pets.
Average Trading Volume: 297,643
Current Market Cap: NOK93.58M
Learn more about LFC0 stock on TipRanks’ Stock Analysis page.